Skip to content
DraconiticResearch
Search Sources API
189,273 studies31 sourcesUpdated 54 min ago
Peer-reviewedCC BYBrain communications

Amygdala volume and psychiatric burden in focal epilepsy: PET evidence for a glial substrate.

  • Theodore P Imhoff-Smith1
  • Alan McMillan1
  • Samuel A Hurley1
  • Mariel Kalkach Aparicio2
  • Veena Nair1
  • Santiago Philibert-Rosas3
  • Jeffrey R Binder4
  • Mary E Meyerand5
  • Jana Jones6
  • Bruce Hermann6
  • Vivek Prabhakaran1,5,6
  • Nagesh Adluru1,7
1 more authors
  • Aaron F Struck3
7 affiliations
  1. 1Department of Radiology, University of Wisconsin-Madison, Madison, WI 53792, USA.
  2. 2Department of Neurology, University of South Dakota, Sioux Falls, SD 57105, USA.
  3. 3Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA.
  4. 4Department of Neurology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  5. 5Department of Medical Physics, University of Wisconsin-Madison, Madison, WI 53705, USA.
  6. 6Department of Neurology, University of Wisconsin-Madison, Madison, WI 53705, USA.
  7. 7Waisman Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Read full textPDFDOICite

Abstract

Temporal lobe epilepsy is of heterogeneous pathology. While many patients present with hippocampal sclerosis and ipsilateral mesiotemporal atrophy, a subgroup of patients without human-detectable sclerosis via structural MRI are characterized by ipsilateral amygdala enlargement and worse postsurgical outcomes. A bidirectional relationship between temporal lobe epilepsy and depression is well-established, with amygdala enlargement and neuroimmune alterations increasingly implicated as substrates for both. In this study, we interrogate the link between amygdala volume and psychiatric burden in temporal lobe epilepsy and evaluate gliosis as a possible substrate. We hypothesize that gliosis drives ipsilateral amygdala volume changes that underlie psychiatric burden in patients with no hippocampal sclerosis. To test these relationships, we analyzed two independent cross-sectional cohorts: (i) a Discovery cohort (43 patients, 80 controls) with structural MRI and robust psychiatric measures and (ii) a Mechanistic pilot cohort (10 patients, 9 controls) with both structural MRI and [¹⁸F]FEPPA PET/MR, an in vivo measure of gliosis, to conceptually replicate and extend findings from the Discovery cohort. Amygdala volumes were assessed with FreeSurfer. Psychiatric burden in the Discovery cohort was assessed with the Depressive Problems subscale from the Achenbach Adult Self-Report. Regional gliosis in the Mechanistic cohort was quantified using [¹⁸F]FEPPA PET, and an exploratory measure of psychiatric burden for this cohort was obtained via medical chart review. In the Discovery cohort, the group without hippocampal sclerosis showed significant ipsilateral enlargement of the whole amygdala, basolateral and central subnuclei compared to controls and the group with sclerosis and a group-dependent association between decreased amygdala volume and increased depressive symptoms. In the Mechanistic cohort, increased [¹⁸F]FEPPA binding was associated with reduced amygdala volume. Adjusting for this effect unmasked significant amygdala enlargement in the group without hippocampal sclerosis. Exploratory analysis revealed a possible central subnucleus-specific relationship between gliosis, volume and psychiatric burden in patients without sclerosis, such that amygdala volume was positively correlated with psychiatric burden specifically in patients with a greater degree of gliosis. These data associate amygdala volume alterations with psychiatric burden in patients without sclerosis and implicate gliosis as a potential mechanistic substrate. Findings support a conceptual shift towards understanding amygdala enlargement not as a static structural phenotype, but as a dynamic, glia-associated state that may confer risk for psychiatric illness. Consequently, patients without hippocampal sclerosis may derive a distinct dual benefit from therapeutic strategies targeted at underlying neuroimmune function.

Related

  1. Infant hippocampal and amygdala volume in an observational follow-up from a randomized clinical trial for maternal prenatal depression
    Catherine H. Demers, Benjamin L. Hankin, LillyBelle K. Deer +6
    Nature CommunicationsPeer-reviewedCC BY 4.0Full text1 citedEpidemiology & public healthCrossref
  2. Neuroinflammation as a shared mechanism linking epilepsy and psychiatric comorbidities
    Beatriz Eiris, Tamiris Prizon, Ana Carolina Medeiros +4
    PsyArXivPreprintCC BY 4.0Full textNeurosciencePsychiatry & mental healthOSF
  3. Childhood Stress and Amygdala-Hippocampal Volume: A Multiverse Analysis in Adolescents
    P. Sivakumar, J. L. Hanson
    medRxivPreprintCC BYFull textPsychiatry & mental healthmedRxiv
  4. Psychiatric comorbidities in pediatric epilepsy: a single-center retrospective study highlighting the burden of depressive symptoms.
    Arianna De Leonardis, Alberto Spalice, Alberto Verrotti +2
    Frontiers in neurologyPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMCCrossref
  5. Progressive Hippocampal Volume Reduction Beyond Normal Aging in Temporal Lobe Epilepsy: A Longitudinal MRI Study.
    Daichi Sone, Yoko Shigemoto, Risa Kagaya +3
    Epilepsia openPeer-reviewedCC BY-NC-NDFull textPsychiatry & mental healthEurope PMC

Cite

BibTeXRIS
BibTeX
@article{imhoffsmith2026amygdala,
  title = {{Amygdala volume and psychiatric burden in focal epilepsy: PET evidence for a glial substrate.}},
  author = {Theodore P Imhoff-Smith and Alan McMillan and Samuel A Hurley and Mariel Kalkach Aparicio and Veena Nair and Santiago Philibert-Rosas and Jeffrey R Binder and Mary E Meyerand and Jana Jones and Bruce Hermann and Vivek Prabhakaran and Nagesh Adluru and Aaron F Struck},
  journal = {Brain communications},
  year = {2026},
  month = oct,
  doi = {10.1093/braincomms/fcag394},
  url = {https://europepmc.org/article/MED/42948645},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Amygdala volume and psychiatric burden in focal epilepsy: PET evidence for a glial substrate.
AU  - Theodore P Imhoff-Smith
AU  - Alan McMillan
AU  - Samuel A Hurley
AU  - Mariel Kalkach Aparicio
AU  - Veena Nair
AU  - Santiago Philibert-Rosas
AU  - Jeffrey R Binder
AU  - Mary E Meyerand
AU  - Jana Jones
AU  - Bruce Hermann
AU  - Vivek Prabhakaran
AU  - Nagesh Adluru
AU  - Aaron F Struck
PY  - 2026
DA  - 2026/10/16
JO  - Brain communications
DO  - 10.1093/braincomms/fcag394
UR  - https://europepmc.org/article/MED/42948645
AB  - Temporal lobe epilepsy is of heterogeneous pathology. While many patients present with hippocampal sclerosis and ipsilateral mesiotemporal atrophy, a subgroup of patients without human-detectable sclerosis via structural MRI are characterized by ipsilateral amygdala enlargement and worse postsurgical outcomes. A bidirectional relationship between temporal lobe epilepsy and depression is well-established, with amygdala enlargement and neuroimmune alterations increasingly implicated as substrates for both. In this study, we interrogate the link between amygdala volume and psychiatric burden in temporal lobe epilepsy and evaluate gliosis as a possible substrate. We hypothesize that gliosis drives ipsilateral amygdala volume changes that underlie psychiatric burden in patients with no hippocampal sclerosis. To test these relationships, we analyzed two independent cross-sectional cohorts: (i) a Discovery cohort (43 patients, 80 controls) with structural MRI and robust psychiatric measures and (ii) a Mechanistic pilot cohort (10 patients, 9 controls) with both structural MRI and [¹⁸F]FEPPA PET/MR, an in vivo measure of gliosis, to conceptually replicate and extend findings from the Discovery cohort. Amygdala volumes were assessed with FreeSurfer. Psychiatric burden in the Discovery cohort was assessed with the Depressive Problems subscale from the Achenbach Adult Self-Report. Regional gliosis in the Mechanistic cohort was quantified using [¹⁸F]FEPPA PET, and an exploratory measure of psychiatric burden for this cohort was obtained via medical chart review. In the Discovery cohort, the group without hippocampal sclerosis showed significant ipsilateral enlargement of the whole amygdala, basolateral and central subnuclei compared to controls and the group with sclerosis and a group-dependent association between decreased amygdala volume and increased depressive symptoms. In the Mechanistic cohort, increased [¹⁸F]FEPPA binding was associated with reduced amygdala volume. Adjusting for this effect unmasked significant amygdala enlargement in the group without hippocampal sclerosis. Exploratory analysis revealed a possible central subnucleus-specific relationship between gliosis, volume and psychiatric burden in patients without sclerosis, such that amygdala volume was positively correlated with psychiatric burden specifically in patients with a greater degree of gliosis. These data associate amygdala volume alterations with psychiatric burden in patients without sclerosis and implicate gliosis as a potential mechanistic substrate. Findings support a conceptual shift towards understanding amygdala enlargement not as a static structural phenotype, but as a dynamic, glia-associated state that may confer risk for psychiatric illness. Consequently, patients without hippocampal sclerosis may derive a distinct dual benefit from therapeutic strategies targeted at underlying neuroimmune function.
SN  - 2632-1297
ER  -